New study observes Real-World progress of kidney disease treatment

NCT ID NCT06242327

Recruiting now Knowledge-focused Sponsor: Mario Negri Institute for Pharmacological Research Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This observational study follows 500 adults with primary membranous nephropathy and nephrotic syndrome who are treated with rituximab or other monoclonal antibodies. Researchers aim to describe long-term disease outcomes and identify predictors of remission or progression. The study does not test a new treatment but gathers real-world data to improve understanding of current therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MEMBRANOUS NEPHROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic membranous glomerulonephritis membranous glomerulonephritis nephrotic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MEMBRANOUS NEPHROPATHY

Contacts and locations

Locations

ASST HPG23 - Unità di Nefrologia
ACTIVE_NOT_RECRUITING

Bergamo, BG, 24127, Italy
Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò"
RECRUITING

Ranica, BG, 24020, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.